The Immunohistochemistry Antibody Market was valued at USD 2.4 billion in 2024 and is expected to reach USD 5 billion by 2035, expanding at a 7.0% CAGR. Increasing cancer diagnostics, personalized medicine initiatives, and research activity are supporting demand for immunohistochemistry antibodies.

Primary antibodies are expected to maintain the largest share among product types because they directly target specific antigens in tissue samples. Secondary antibodies, isotype controls, and biotinylated antibodies also contribute to diagnostic and research workflows, including signal enhancement and assay validation.

Cancer diagnostics represents the largest application segment, valued at USD 1.3 billion in 2024 and projected to reach USD 2.5 billion by 2035. Infectious disease diagnosis, vaccine development, and research and development provide additional applications for IHC antibody technologies.

Automation and digital pathology are becoming important areas of technological development. Automated immunohistochemistry can support higher throughput and consistency, while digital imaging and AI-enabled analysis are creating opportunities for more data-driven pathology workflows.